Sildenafil
An FDA-approved phosphodiesterase-5 inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Sildenafil
An FDA-approved phosphodiesterase-5 inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension.
Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.
Regulatory statement in source: FDA-approved.
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor approved by the FDA on March 27, 1998, as the first oral medication for erectile dysfunction. Subsequently approved for pulmonary arterial hypertension to improve exercise ability and delay clinical worsening in adults and pediatric patients (1-17 years). Under Viagra brand for ED; Revatio brand for PAH.
Benefits reported in the imported source
- Erectile dysfunction in adults.
- Pulmonary arterial hypertension to improve exercise ability.
Risks and limits
- Headache
- Flushing
- Dyspepsia
- Nasal congestion
- Vision changes
- Priapism (rare)
- Cardiovascular events in susceptible patients
Source bottom line: FDA-approved PDE5 inhibitor with established efficacy for two distinct approved indications.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
Adult men with erectile dysfunction
- Reported regimen
- Oral phosphodiesterase-5 inhibitor; response dependent on sexual stimulation
- Duration
- As-needed use per FDA indication
- Reported outcome
- Improves erectile function compared to placebo
- Source
- FDA Approves Impotence Pill, Viagra - ScienceDaily
Claim provenance
evidence.json#/catalog:medication:sildenafil/protocols/0
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Historical research outcome: no-verified-description · 2026-10-06
No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.
- https://www.nhs.uk/medicines/sildenafil-viagra/: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.
Pharmacokinetic context
Historical half-life estimate: 4 hours. FDA label, Viagra: parent and active N-desmethyl metabolite half-life about 4 hours Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- Label: SILDENAFIL CITRATE tablet - DailyMed
- Sildenafil - StatPearls (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
- FDA Approves Impotence Pill, Viagra - ScienceDaily
Snapshot provenance
Source ID: catalog:medication:sildenafil. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.